Analysts Offer Predictions for Checkmate Pharmaceuticals’ Q3 2020 Earnings (NASDAQ:INBX)

Checkmate Pharmaceuticals (NASDAQ:INBX) – Equities research analysts at Jefferies Financial Group issued their Q3 2020 earnings estimates for shares of Checkmate Pharmaceuticals in a research report issued to clients and investors on Monday, September 14th. Jefferies Financial Group analyst M. Yee anticipates that the company will post earnings of ($0.56) per share for the quarter. Jefferies Financial Group has a “Buy” rating and a $30.00 price target on the stock. Jefferies Financial Group also issued estimates for Checkmate Pharmaceuticals’ Q4 2020 earnings at ($0.58) EPS, FY2020 earnings at ($2.42) EPS, FY2021 earnings at ($2.20) EPS, FY2022 earnings at ($2.26) EPS and FY2023 earnings at ($2.50) EPS.

A number of other brokerages have also commented on INBX. Evercore ISI assumed coverage on Checkmate Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $30.00 target price for the company. Credit Suisse Group assumed coverage on Checkmate Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $26.00 target price for the company.

Shares of INBX stock opened at $17.29 on Wednesday. Checkmate Pharmaceuticals has a 12 month low of $15.76 and a 12 month high of $26.98.

In other news, major shareholder Global Investors Lp Viking bought 180,219 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was acquired at an average cost of $18.92 per share, for a total transaction of $3,409,743.48. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

About Checkmate Pharmaceuticals

Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors.

Recommended Story: Cost of Capital Explained

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.